Body dysmorphic disorder (BDD) is an obsessive-compulsive and related disorder that is common and usually causes substantial distress and impairment in psychosocial functioning. BDD is associated with markedly poor quality of life and high rates of suicidal ideation and behavior. The first-line pharmacologic approach is a serotonin reuptake inhibitor, often at relatively high doses; serotonin reuptake inhibitors are also recommended for patients with delusional BDD beliefs. The firstline psychosocial treatment is manualized cognitive-behavioral therapy that is tailored to BDD's unique clinical features; it is not recommended that therapists simply apply cognitive-behavioral approaches for other disorders, such as obsessivecompulsive disorder (OCD). Because insight is so often absent or poor in BDD, motivational interviewing techniques are often needed to engage and retain patients in treatment. Cosmetic treatment (e.g., surgery or dermatologic treatment) is not recommended because it appears to only rarely improve BDD symptoms and can even make them worse. BDD has many similarities to OCD and is probably closely related to OCD, but the two disorders also have some important differences. From a clinical perspective, the most important differences are that BDD is characterized by poorer insight, more frequent comorbid major depressive disorder and substance use disorders, and more frequent suicidality. Although treatment approaches have similarities to those for OCD, effective cognitive-behavioral therapy for BDD meaningfully differs from that for OCD.